Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Decrease in Short Interest
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Decrease in Short Interest
Capricor Therapeutics Inc (NASDAQ:CAPR – Get Rating) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 358,500 shares, a drop of 9.1% from the July 15th total of 394,500 shares. Based on an average daily volume of 113,700 shares, the days-to-cover ratio is currently 3.2 days.
卡布里科治療公司(納斯達克:CAPR-GET評級)看到空頭股數在7月份大幅下降。截至7月31日,空頭股數共有358,500股,較7月15日的394,500股下降了9.1%。根據日均成交量113,700股計算,目前天數與回補比率為3.2天。
Capricor Therapeutics Trading Up 3.1 %
Capricor Treateutics股價上漲3.1%
NASDAQ CAPR opened at $5.26 on Thursday. Capricor Therapeutics has a 52 week low of $2.56 and a 52 week high of $5.85. The company has a 50 day moving average price of $4.38 and a 200 day moving average price of $4.03.
納斯達克週四開盤報5.26美元。Capricor Treateutics的52周低點為2.56美元,52周高點為5.85美元。該公司的50日移動均線價格為4.38美元,200日移動均線價格為4.03美元。
Capricor Therapeutics (NASDAQ:CAPR – Get Rating) last issued its quarterly earnings results on Wednesday, August 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). During the same period last year, the business earned ($0.21) earnings per share. As a group, equities analysts forecast that Capricor Therapeutics will post -1.17 EPS for the current year.
卡布里科治療公司(納斯達克代碼:CAPR-GET Rating)最近一次發佈季度收益報告是在8月10日星期三。這家生物技術公司公佈的季度每股收益(EPS)為0.29美元,低於分析師普遍預期的0.25美元和0.04美元。去年同期,該業務實現每股收益0.21美元。作為一個整體,股票分析師預測,Capricor Treateutics本年度的每股收益將達到1.17。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Insiders Place Their Bets
內部人士下注
In other Capricor Therapeutics news, Director David B. Musket sold 28,215 shares of the company's stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $3.77, for a total value of $106,370.55. Following the completion of the sale, the director now directly owns 12,747 shares in the company, valued at approximately $48,056.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director David B. Musket sold 17,775 shares of the business's stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $4.44, for a total value of $78,921.00. Following the completion of the transaction, the director now owns 40,962 shares of the company's stock, valued at $181,871.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David B. Musket sold 28,215 shares of the company's stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $3.77, for a total value of $106,370.55. Following the sale, the director now owns 12,747 shares of the company's stock, valued at approximately $48,056.19. The disclosure for this sale can be found here. 9.00% of the stock is currently owned by company insiders.
另外,董事大衞·B·穆斯克特在6月29日(星期三)的一次交易中出售了28,215股該公司股票。這隻股票的平均售價為3.77美元,總價值為106,370.55美元。出售完成後,董事現在直接擁有該公司12,747股,價值約48,056.19美元。這筆交易是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份文件中披露的,可以通過這個鏈接獲得。在相關新聞中,董事大衞·B·馬科特在6月27日(星期一)的一筆交易中出售了17,775股該公司的股票。這些股票的平均價格為4.44美元,總價值為78,921.00美元。交易完成後,董事現在擁有40,962股該公司股票,價值181,871.28美元。這筆交易是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份法律文件中披露的,可以通過這個鏈接訪問。此外,在6月29日週三的一筆交易中,董事大衞·B·馬斯基特出售了28,215股新浪微博股票。這隻股票的平均售價為3.77美元,總價值為106,370.55美元。交易完成後,董事現在持有該公司12,747股股票,價值約48,056.19美元。此次拍賣的披露信息可在此處找到。9.00%的股份目前由公司內部人士持有。
Institutional Investors Weigh In On Capricor Therapeutics
機構投資者看好Capricor Treateutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Selective Wealth Management Inc. purchased a new stake in shares of Capricor Therapeutics during the first quarter worth about $732,000. Vanguard Group Inc. increased its stake in Capricor Therapeutics by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 1,020,998 shares of the biotechnology company's stock valued at $3,502,000 after purchasing an additional 54,260 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Capricor Therapeutics by 54.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 148,768 shares of the biotechnology company's stock valued at $510,000 after purchasing an additional 52,611 shares in the last quarter. Bailard Inc. purchased a new position in shares of Capricor Therapeutics in the second quarter worth $104,000. Finally, UBS Group AG grew its holdings in shares of Capricor Therapeutics by 326.0% during the second quarter. UBS Group AG now owns 29,352 shares of the biotechnology company's stock valued at $102,000 after buying an additional 22,462 shares during the last quarter. 9.49% of the stock is currently owned by hedge funds and other institutional investors.
一些對衝基金和其他機構投資者最近增持或減持了該業務的股份。選擇性財富管理公司在第一季度購買了Capricor Treateutics價值約73.2萬美元的新股。先鋒集團在第一季度增持了Capricor Treateutics 5.6%的股份。先鋒集團(Vanguard Group Inc.)現在持有這家生物技術公司1,020,998股股票,價值3,502,000美元,該公司在上個季度又購買了54,260股票。Dimension Fund Advisors LP在第一季度將其在Capricor Treateutics的持股增加了54.7%。Dimension Fund Advisors LP現在擁有這家生物技術公司148,768股股票,價值51萬美元,上個季度又購買了52,611股。Bailard Inc.在第二季度購買了價值10.4萬美元的Capricor Treateutics新股頭寸。最後,瑞銀集團在第二季度增持了326.0%的Capricor Treateutics股票。瑞銀集團(UBS Group AG)現在擁有29,352股這家生物技術公司的股票,價值10.2萬美元,上個季度又購買了22,462股。該公司9.49%的股票目前由對衝基金和其他機構投資者持有。
Capricor Therapeutics Company Profile
Capricor治療公司簡介
(Get Rating)
(獲取評級)
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
卡布里科治療公司(納斯達克代碼:CAPR)是一家臨牀階段的生物技術公司,專注於治療罕見疾病的一流生物療法的發現、開發和商業化。Capricor的主要候選藥物CAP-1002是一種異基因細胞療法,目前正在臨牀開發中,用於治療Duchenne肌營養不良症。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Capricor Therapeutics (CAPR)
- Which Semiconductor Stocks Are Ready For Big Price Moves?
- Miners Advance On Earnings Despite Broader Economic Challenges
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe's Stands Out Amid Q2 Retail Reports
- Target's Results Cap Upside Potential For Retail Stocks
- 免費獲取StockNews.com關於Capricor治療(CAPR)的研究報告
- 哪些半導體類股準備好迎接價格大幅波動?
- 儘管面臨更廣泛的經濟挑戰,礦商的收益仍在上漲
- 安捷倫科技對Illumina證明瞭自己的價值
- Lowe‘s在第二季度零售報告中脱穎而出
- 塔吉特的業績上限零售類股的上行潛力
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Capricor Treateutics Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Capricor Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。